(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT03731260 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

251

Enrollment

INDUSTRY

Sponsor class

Conditions

Indolent Systemic Mastocytosis

Interventions

DRUG: Avapritinib
DRUG: Placebo

Sponsor

Blueprint Medicines Corporation